Every 8-K that Tao Synergies Inc. (TAOX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TAOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TAOX filings page.
TAO Synergies Inc. (TAOX) entered a financing agreement to raise gross proceeds of $11.0 million through a private placement of 11,000 shares of Series E convertible preferred stock with a stated value of $1,000 per share, alongside warrants. The preferred is initially convertible at $8.00 per share into up to 1,375,000 common shares, and investors also receive warrants to purchase up to 1,375,000 common shares at $8.00, expiring five years from issuance.
The preferred pays cash dividends at 7% per annum, increasing to 15% upon a Triggering Event, and votes with common stock based on stated value divided by the then‑applicable conversion price, with a floor tied to Nasdaq’s “Minimum Price.” Issuances are limited to 19.99% of outstanding common stock absent stockholder approval; the company plans a vote by December 31, 2025. Registration rights require filing a resale registration for 150% of the conversion and warrant shares, with liquidated damages for delays. GP Nurmenkari Inc. acts as placement agent, earning an 8% cash fee plus a $10,000 due diligence fee and placement agent warrants (4% of initial conversion shares).
The company expects to close on October 15, 2025, and use net proceeds for general corporate purposes and working capital. TAO also terminated a consulting agreement with Dr. Daniel L. Alkon on October 3, 2025, retaining potential incentive fee obligations for certain Bryostatin transactions for one year post‑termination, and appointed Bruce Bernstein as Vice‑Chairman of the Board effective October 1, 2025.
TAO Synergies Inc. reported several governance and advisory changes. Two directors, Jonathan Schechter and Dr. Alan Tuchman, voluntarily resigned from the board and all board committees, with the company stating their departures were not due to any disagreement with its operations, policies or practices. Dr. Tuchman will continue to serve as Chief Medical Officer.
To fill the vacancies, the company appointed Robert Ephron to the board and to the audit, compensation, and nominating and corporate governance committees. Ephron, who has extensive advertising and sales experience at JK Polk Holdings, Paramount, and Viacom, waived his initial option grant under the non-employee director compensation policy.
TAO Synergies also engaged Joseph Jacks as an advisor to its digital asset treasury strategy and entered into a one-year consulting agreement with him. As part of this agreement, the company issued warrants exercisable for 100,000 shares of common stock at an exercise price of $8.40 per share, with a five-year expiration from the date of issuance.
TAO Synergies Inc. stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan, increasing the number of shares reserved for issuance by 2,000,000 to 2,675,000 shares. At the Special Meeting, holders of 567,847 shares, or approximately 35.23% of outstanding common stock, were present in person or by proxy, constituting a quorum.
Stockholders also authorized, for Nasdaq compliance, the issuance of common stock underlying convertible preferred stock and warrants issued under certain June 2025 agreements in an amount equal to or in excess of 20% of the Company’s common stock outstanding before those issuances. Final vote totals were: Proposal 1 — For 500,450, Against 66,872, Abstain 525; Proposal 2 — For 492,781, Against 73,988, Abstain 1,078; Proposal 3 — For 523,728, Against 42,865, Abstain 1,254. The Amended and Restated Equity Incentive Plan is filed as Exhibit 10.1.